Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
HIV-1 Protease Inhibitor
L 694746 is a potent inhibitor of HIV-1 protease, demonstrating an IC50 value of 1 nM and a Ki of 0.34 nM. This compound exhibits strong antiviral activity, making it a valuable reagent in the study of HIV replication and resistance mechanisms. Its effectiveness in inhibiting protease activity underscores its potential applications in HIV research and therapeutic development. -
HIV-1 Inhibitor
DMJ-I-228 is a CD4-mimetic compound that targets HIV-1 by binding to the gp120 protein within the conserved Phe 43 cavity, which is adjacent to the CD4-binding site. This interaction effectively obstructs the binding of CD4, leading to the inhibition of HIV-1 infection. DMJ-I-228 is utilized in research focused on HIV-1 entry mechanisms and the development of antiviral therapies. -
HIV Protease Inhibitor
DMP-851 is a potent cyclic urea inhibitor of HIV protease, exhibiting a Ki of 0.021 nM. It demonstrates significant antiviral activity against both laboratory strains of HIV-1 and HIV-2, as well as primary clinical isolates that are resistant to Zidovudine. This compound serves as an important tool for research into HIV treatment and resistance mechanisms. -
HIV Inhibitor
DAPD-NHc-pr is an HIV inhibitor that demonstrates potent antiviral activity with EC50 and EC90 values of 0.85 μM and 13 μM, respectively. This compound exhibits minimal toxicity to normal cells, including peripheral blood mononuclear cells (PBM), CEM, and VERO cell lines. DAPD-NHc-pr is valuable for studying HIV replication and exploring potential therapeutic strategies against HIV infection. -
HIV Protease Inhibitor
BILA 1906 BS is a potent HIV protease inhibitor that disrupts HIV-1 replication by inhibiting the protease-mediated cleavage of Gag and Gag-Pol polyprotein precursors during virion maturation. This compound effectively blocks the maturation of p24 proteins in wild-type HIV-1, thereby impairing polyprotein processing and viral maturation. BILA 1906 BS is valuable for research focused on human immunodeficiency virus type 1 (HIV-1) infection and its associated cellular mechanisms. -
HIV Inhibitor
HIV-1 inhibitor-72 is a potent inhibitor targeting the HIV-1 virus. Its primary mechanism involves binding to essential viral proteins, effectively inhibiting viral replication. This compound is valuable for research in virology and HIV-related studies, particularly in the development of therapeutics aimed at eradicating HIV-1 infection. -
HIV-1 Inhibitor
HIV-1 inhibitor-27 is a potent inhibitor targeting HIV-1, exhibiting IC50 values of 16 μM, 0.5 μM, and 0.39 μM against HIV-1 YU2, NL4-3, and 89.6 strains, respectively. This compound demonstrates low cytotoxicity, with a CC50 of 128 μM in TZM-bl cells. HIV-1 inhibitor-27 is suitable for research applications focused on understanding and combating AIDS-related mechanisms. -
HIV-1 Inhibitor
(+)-PM 92131 is a non-nucleoside inhibitor of HIV-1 that specifically targets viral replication. It demonstrates significant anti-HIV-1 activity with EC50 values of 0.8 μM and 0.6 μM against the HIV-1 RF strain, as evidenced by XTT cytoprotection and syncytium-forming assays, respectively. This compound is suitable for research applications focused on HIV infections and the mechanisms of viral inhibition. -
HIV-1 Reverse Transcriptase Inhibitor
L 697661 is an orally active inhibitor of HIV-1 reverse transcriptase, targeting the essential enzyme required for the replication of the virus. This compound demonstrates potent antiviral activity against HIV-1, making it a valuable tool for research in HIV treatment and therapies. Its ability to interrupt viral replication pathways provides critical insights into antiviral drug development and therapeutic efficacy studies. -
HIV-1 Inhibitor
HIV-1 Inhibitor-26 is a potent inhibitor of HIV-1 reverse transcriptase (RT), demonstrating an IC50 value of 1.4 μM. This compound exhibits low cytotoxicity, with a CC50 of 1486 μM in peripheral blood mononuclear cells (PBMCs). HIV-1 Inhibitor-26 is suitable for research applications focused on AIDS and the mechanisms of HIV replication. -
HIV Inhibitor
Nevirapine quinone methide is an active metabolite of Nevirapine, functioning as a non-nucleoside reverse transcriptase inhibitor (NNRTI) targeting HIV-1. This compound is utilized in research to explore its antiviral properties and the mechanisms behind its associated toxicities, including severe skin and liver injuries resulting from its metabolic activation. Additionally, Nevirapine quinone methide has been identified as an inhibitor of CYP3A4, which may further elucidate its hepatic toxicity in studies focused on drug metabolism and safety. -
HIV Inhibitor
BMS-663749 lysine is a prodrug of an HIV-1 attachment inhibitor that enhances the bioavailability of the parent compound upon oral administration. This compound exhibits potent antiviral activity against HIV-1 by blocking the virus's ability to bind to host cells. Research applications include studying HIV-1 entry mechanisms and exploring therapeutic strategies for HIV infection. -
HIV-1 RT Inhibitor, HIV-1 Inhibitor
S-2720 is a potent inhibitor of HIV-1 reverse transcriptase (HIV-1 RT) and effectively suppresses HIV-1 replication. It binds to overlapping sites on the enzyme, likely targeting a pocket within the p66 subunit, which is critical for reverse transcription. As a quinoxaline derivative, S-2720 demonstrates significant potential for advancing research in HIV-1 infection and developing therapeutic strategies against this virus. -
HIV Inhibitor
HI-253 is a non-nucleoside inhibitor of HIV-1 reverse transcriptase, exhibiting significant antiviral activity against both resistant and sensitive strains of HIV-1. This compound serves as a valuable tool for research focused on HIV treatment and the mechanisms of viral resistance, making it essential for studies aimed at developing new therapeutic strategies against HIV. -
HIV Inhibitor
[(Cys(Bzl)84,Glu(OBzl)85)]CD4 (81-92) functions as a selective inhibitor of HIV-1 by obstructing the interaction between the virus and CD4 molecules. This compound demonstrates significant antiviral activity by effectively inhibiting viral infection and cell fusion. Research applications include studies focused on HIV treatment mechanisms and exploration of CD4 receptor interactions, with complete inhibition of fusion formation observed at a concentration of 25 μM. -
HIV Inhibitor
HIV-1 protease-IN-1 is a highly potent inhibitor of the HIV-1 protease, exhibiting an IC50 of 90 pM. This compound demonstrates significant antiviral activity, with EC50 values of 89 nM against the B-HIV strain and 13.59 nM against the C-HIV strain ZM246, as well as an impressive EC50 of 8.23 nM against the C-HIV strain Indie. HIV-1 protease-IN-1 serves as a valuable tool for research and development in HIV treatment strategies and antiviral drug discovery. -
HIV-1 gp120 Inhibitor
gp120-IN-1 is a potent inhibitor targeting the HIV-1 gp120 protein. It demonstrates significant anti-HIV-1 activity with an IC50 value of 2.2 µM, while exhibiting a CC50 of 100.90 µM in SUP-T1 cells, indicating dose-dependent cytotoxicity. This compound effectively inhibits gp120-mediated viral entry into host cells, making it a valuable tool for research in HIV therapeutics and virology studies. -
HIV Inhibitor
Tenofovir-C3-O-C12-trimethylsilylacetylene ammonium is a potent HIV inhibitor that demonstrates significantly prolonged half-life values compared to tenofovir in human liver microsomes. This compound exhibits robust anti-HIV activity in vitro and shows enhanced pharmacokinetic properties in vivo. Additionally, it serves as a click chemistry reagent featuring an alkyne group, which allows for copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules, facilitating various research applications in medicinal chemistry and drug development. -
HIV-1 Protease Inhibitor
CGP 53437 is a potent HIV-1 protease inhibitor, exhibiting a Ki value of 0.2 nM. This compound effectively inhibits HIV replication, making it a valuable tool for research focused on HIV pathogenesis and antiviral therapy development. Its oral bioactivity supports studies in pharmacokinetics and therapeutic interventions against HIV. -
HIV Inhibitor
(-)-6-Aminocarbovir is an antiviral compound that acts as a potent inhibitor of HIV replication. It demonstrates significant biological activity against the virus, making it a valuable tool in HIV research. This reagent is applicable for studies focusing on viral infections and the development of antiviral therapies. -
HIV-1 Reverse Transcriptase Inhibitor
U 88204 is a potent inhibitor of HIV-1 reverse transcriptase, exhibiting an IC50 value of 0.25 μM. This compound effectively blocks the replication of HIV-1 in infected cells, making it a valuable tool for research focused on HIV infection and acquired immunodeficiency syndrome (AIDS). Its specificity and efficacy facilitate studies aimed at understanding the mechanisms of viral replication and the development of antiviral therapies. -
HIV Inhibitor
VCH-286 is a selective CCR5 inhibitor that demonstrates significant in vitro activity against HIV-1. This compound effectively blocks the CCR5 co-receptor, preventing viral entry into host cells. VCH-286 is particularly useful for research applications focused on understanding HIV-1 pathogenesis and developing therapeutic strategies targeting CCR5-mediated viral infections. -
HIV-1 Inhibitor
HIV-1 inhibitor-61 is a potent inhibitor of HIV-1 reverse transcriptase, demonstrating an EC50 of 0.07 nM in NL4-3 wild-type MT-4 cells. This compound effectively disrupts viral replication, making it a valuable tool in HIV research and the development of antiviral therapies. Its high efficacy positions it as an essential reagent for studying HIV-1 pathogenesis and potential therapeutic interventions. -
HIV-1 Reverse Transcriptase Inhibitor
BRN3OMe is a potent inhibitor of HIV-1 reverse transcriptase, specifically targeting the enzyme essential for the replication of the HIV-1 virus. This compound demonstrates significant antiviral activity, making it a valuable tool in the study of HIV replication and the development of antiviral agents. Researchers may utilize BRN3OMe to explore mechanisms of inhibition and therapeutic applications in HIV treatment strategies. -
HIV Protease Inhibitor
JE-2147 is a potent dipeptide inhibitor of HIV protease, exhibiting a Ki value of 0.33 nM for HIV-1 protease. This compound demonstrates effective antiviral activity against a broad range of HIV strains, including HIV-1, HIV-2, simian immunodeficiency virus, and various clinical isolates of HIV-1 in vitro. JE-2147 serves as a valuable tool for research into HIV protease inhibition and the development of antiretroviral therapies. -
HIV Inhibitor
HIV-IN-4 is a potent inhibitor of HIV, targeting key viral replication processes. This compound demonstrates significant anti-HIV activity, making it a valuable tool for research into HIV therapeutics and antiviral strategies. Its efficacy supports investigations into mechanisms of resistance and the development of novel treatment approaches for HIV-infected individuals. -
HIV-1 Inhibitor
18A is a reversible broad-spectrum inhibitor of HIV-1 that targets the envelope protein (Env) to block viral entry. This compound demonstrates significant inhibitory activity against various HIV-1 strains, making it a valuable tool for HIV research and therapeutic development. Its mechanism of action positions 18A as a potential candidate for studying viral resistance and the development of novel antiviral strategies. -
HIV-1 Reverse Transcriptase Ribonuclease H Inhibitor
GSK5750 is a specific and potent inhibitor of HIV-1 reverse transcriptase ribonuclease H, exhibiting an IC50 value of 0.33 μM. This compound functions through a metal-ion chelation mechanism at the RNase H active site. GSK5750 is valuable for research into HIV replication and the development of antiviral strategies targeting reverse transcriptase. -
HIV Inhibitor
HIV p17 Gag (77-85) is an HLA-A*0201-restricted cytotoxic T lymphocyte (CTL) epitope that serves as an HIV inhibitor. This peptide is critical for studies aimed at understanding immune responses to HIV infection and developing immunotherapeutic strategies. It can be employed to evaluate T cell responses and facilitate vaccine design within HIV research applications. -
HIV-1 Inhibitor
(±)-PM 92131 is a non-nucleoside inhibitor targeting HIV-1. It demonstrates significant anti-HIV-1 activity with IC50 values of 45.7 μM and 53.8 μM against the HIV-1 RF strain, as assessed in XTT cytoprotection and syncytium-forming assays, respectively. This compound is suitable for research applications focused on HIV infections and the development of antiviral strategies. -
HIV inhibitor
F9170 is an amphipathic peptide that serves as an inhibitor of HIV-1, effectively inactivating the virus by targeting the conserved cytoplasmic tail of the HIV-1 envelope protein. By disrupting the integrity of the viral membrane, F9170 demonstrates strong antiviral activity. Additionally, this compound possesses the ability to cross the blood-brain barrier, making it a relevant candidate for research applications focused on HIV treatment, particularly in the context of central nervous system involvement. -
HIV-1 Capsid Inhibitor
HIV-1 Capsid Inhibitor 1 targets the HIV-1 capsid, demonstrating significant antiviral activity with an EC50 value of 3.13 µM. This compound serves as a valuable tool in HIV research, providing insights into viral replication mechanisms and potential therapeutic interventions. Its ability to inhibit viral capsid formation makes it a critical reagent for the study of HIV-1 pathogenicity and the development of novel antiviral strategies. -
HIV Inhibitor
Mer-NF5003E is a non-nucleoside reverse transcriptase inhibitor targeting HIV-1 reverse transcriptase, with an EC50 value of 50 μM. This compound demonstrates inhibitory activity against both wild-type HIV-1 and various NNRTI-resistant strains, including K103N and Y181C. Mer-NF5003E serves as a valuable tool for research focused on HIV infections and the development of therapeutic strategies to combat resistant viral strains. -
HIV-1 Reverse Transcriptase Inhibitor
Melanochromone is an inhibitor of HIV-1 reverse transcriptase, demonstrating significant anti-HIV-1 activity. This compound is utilized in research focusing on HIV-1 infection and its mechanisms, contributing to the understanding of viral replication and potential therapeutic interventions. -
HIV-1 RT Inhibitor
Nigranoic acid is a triterpenoid that inhibits HIV-1 reverse transcriptase, presenting potential applications in antiviral research. Additionally, Nigranoic acid demonstrates neuroprotective effects by engaging the PARP/AIF signaling pathway, as evidenced in cerebral ischemia-reperfusion models. This dual activity positions Nigranoic acid as a valuable compound for further investigation in HIV treatment and neuroprotection studies. -
HIV Inhibitor
12-Oxocalanolide A is a potent inhibitor of HIV-1 reverse transcriptase, exhibiting an IC50 of 2.8 μM and an EC50 of 12 μM. This compound serves as an analogue of Calanolide, demonstrating significant antiviral activity against human immunodeficiency virus type 1. It is valuable for research in virology and the development of anti-HIV therapeutics. -
HIV Protease Inhibitor
CGP 53820 is a potent inhibitor of HIV protease, demonstrating Ki values of 9 nM for HIV-1 protease and 53 nM for HIV-2 protease. This compound effectively disrupts the enzymatic activity critical for the replication of HIV, making it a valuable tool in AIDS research and the study of antiretroviral therapies. Its specificity and efficacy support investigations into HIV resistance and the development of novel therapeutic strategies. -
HIV Inhibitor
HIV-1 Inhibitor-37 is a potent inhibitor of HIV-1, targeting viral replication pathways. It has demonstrated efficacy in reversing latency, presenting valuable potential for development as a novel therapeutic agent. This compound is suitable for research applications focused on HIV latency and the mechanisms of viral eradication. -
HIV-1 Capsid Protein Inhibitor
I-XW-053 sodium is an inhibitor of the HIV-1 capsid protein, demonstrating significant antiviral activity against HIV-189BZ167 with an IC50 value of 164.2 μM. This compound effectively disrupts the interaction between the N-terminal domains of the capsid protein, specifically at the NTD-NTD interface, exhibiting micromolar affinity. I-XW-053 is a valuable tool for research aimed at understanding HIV replication and developing therapeutic strategies against HIV infection. -
HIV-1 Capsid Inhibitor
HIV-1 Inhibitor-17 is a potent HIV-1 capsid inhibitor, demonstrating significant antiviral activity with an EC50 value of 2.57 μM against the HIV-1 NL4-3 strain. This compound exhibits certain cytotoxicity, with a CC50 value greater than 8.55 in MT-4 cells. It is valuable for research applications aimed at understanding HIV-1 replication and developing effective therapeutic strategies. -
HIV-1 Reverse Transcriptase Inhibitor
DPC-082 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) targeting HIV-1. It demonstrates significant antiviral activity, with an IC90 of 2.0 nM against wild-type RF virus. Additionally, DPC-082 effectively inhibits a variety of single and multiple amino acid substituted HIV-1 mutant strains, making it a valuable tool for research into HIV resistance mechanisms and therapeutic development. -
HIV Inhibitor
Fostemsavir sodium is an HIV-1 attachment inhibitor that demonstrates antiviral activity against multidrug-resistant strains of HIV-1. This compound not only hinders viral entry but also exhibits potential effects in reducing markers associated with monocyte activation and coagulation abnormalities. Its applications include research on HIV pathogenesis, treatment resistance, and the immune response in HIV-infected individuals. -
HIV-1 Protease Inhibitor
Mozenavir is a potent inhibitor of HIV-1 protease, exhibiting a Ki value of 0.3 nM. By obstructing the cleavage and processing of viral polyproteins, Mozenavir effectively inhibits the replication and maturation of HIV-1. This compound holds significant promise for advancing research on HIV infection and its associated therapeutic strategies. -
HIV Inhibitor
HIV-IN-13 is a potent HIV inhibitor that effectively targets the virus in CEM-SS cells with an EC50 of 1.38 μM. It exhibits antiviral activity against various HIV strains in human peripheral blood mononuclear cells (hPBMCs), demonstrating EC50 values ranging from 2.01 to 10.7 μM, while maintaining low cellular toxicity (TC50 > 100 μM). This compound is suitable for research applications focused on HIV infection and its mechanisms of action. -
HIV Inhibitor
HIV-1 inhibitor-57 is a potent HIV-1 inhibitor that targets reverse transcriptase (RT). Demonstrating activity against both wild-type and several prevalent non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-1 strains, it exhibits effective EC50 values between 0.024 to 0.0010 μM. This compound enhances binding through additional interactions with critical residues in the HIV-1 RT binding site, making it a valuable tool for HIV research and antiviral drug development. -
HIV-1 Inhibitor
HIV-1 inhibitor-31 is a potent inhibitor targeting the HIV-1 virus. This compound demonstrates significant antiviral activity against HIV-1, making it a valuable tool for AIDS research. Its effectiveness in inhibiting viral replication allows for the investigation of novel therapeutic approaches in the treatment of HIV infection. -
HIV-1 Inhibitor
Rhuscholide A is a benzofuran lactone that primarily inhibits HIV-1 activity. It exhibits significant antiviral potency, with an EC50 value of 1.62 μM. This compound is useful in research focused on the development of HIV therapies and studying viral replication mechanisms. -
HIV Inhibitor
Aureothin is a natural polyketide that functions as an HIV inhibitor, exhibiting an IC50 of 5.3 nM. This compound demonstrates significant antiviral activity, making it a valuable tool in HIV research. Additionally, Aureothin shows potential as a microbial biolarvicide, offering applications in ecological studies involving pest control and microbial interactions. -
HIV-1 Inhibitor
HIV-1 inhibitor-42 is a potent inhibitor of HIV-1 with an IC50 of 0.06 μM. This compound exerts its antiviral effects by targeting HIV-1 reverse transcriptase, inhibiting both RNA-dependent DNA polymerase and DNA-dependent DNA polymerase activities, with IC50 values of 0.518 μM and 0.072 μM, respectively. It serves as a valuable tool for studying HIV-1 replication and for the development of antiviral therapies. -
HIV-1 Inhibitor
HIV-IN peptide is a competitive inhibitor of HIV-1 protease, exhibiting an inhibitory constant (Ki) of 50 nM. This peptide plays a crucial role in the study of HIV-1 replication by disrupting the proteolytic processing of viral proteins. It is primarily utilized in research applications focused on antiviral drug development and the understanding of HIV biology.
